Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NM32-2668 |
| Synonyms | |
| Therapy Description |
NM32-2668 is a trispecific T-cell engager that targets ROR1, CD3epsilon, and human serum albumin, which potentially induces T-cell proliferation and activation and tumor cell lysis (Journal for ImmunoTherapy of Cancer 2021;9). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NM32-2668 | NM32-2668 is a trispecific T-cell engager that targets ROR1, CD3epsilon, and human serum albumin, which potentially induces T-cell proliferation and activation and tumor cell lysis (Journal for ImmunoTherapy of Cancer 2021;9). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06299163 | Phase I | NM32-2668 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Terminated | USA | 0 |